Britain and America have announced a significant commercial pact that will maintain zero tariffs on UK medicine exports entering the US market.
Key Provisions of the Accord
As part of the deal, the UK has committed to boost spending on drugs through the public health system. This move ensures that tariffs on these key products will be held at nothing for a period of the next three years.
This agreement is in response to earlier statements to hike duties on branded drug imports, with figures mentioned reaching double the cost.
"This deal with the United Kingdom strengthens the international landscape for innovative medicines and introduces much-needed fairness to American-British drug exports," a statement declared.
Trade Impact
Medicines represent one of the Britain's most significant exports to the US, which is by far the largest destination for leading UK drugmakers.
Trade data show that in the year leading up to last September, the UK sold pharmaceutical products worth £11.1bn to the US. This figure represented a significant portion of all goods exports in that timeframe.
"This agreement secures work, boosts capital expenditure and sets the stage for the UK to become a international leader for life sciences," the Business and Trade Secretary stated.
Key UK Commitments
The pact entails several key changes from the British government:
- Higher Cost Ceiling: The UK will lift the price threshold at which it judges new treatments to be unaffordable by 25%.
- Increased NHS Spending: There is a target to double overall public funding on drugs from 0.3% of GDP to 0.6 percent over the next decade.
- Rebate Cap: The percentage pharmaceutical firms must return to the NHS to prevent overspending will be restricted at 15%. In the past, refunds topped 20%.
Industry Background
The deal takes place against a protracted dispute between the drug companies and the British authorities over spending levels and NHS adoption.
The disagreement were exacerbated by claims that US customers were paying a premium for the equivalent treatments than people in the other developed nations.
In recent months, several large pharmaceutical investments in the UK have been delayed or scrapped, while substantial funding commitments have been announced toward US facilities.
The Science Minister stated that the NHS needed to spend more on treatments, noting that its budget allocation on drugs had shrunk as a percentage of its overall budget over the last ten years.
